Home » Healthcare » Pharmaceuticals » Novel Drug Delivery Systems (NDDS) Market

Novel Drug Delivery Systems (Ndds) Market By Route of administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery System) By Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Price: $4999

Published: | Report ID: 14202 | Report Format : PDF

Actionable Insights Delivered – novel drug delivery systems Market Size

Positioned with a USD 12.1 billion valuation in 2022, the novel drug delivery systems Market asserted its global eminence. Set to scale to USD 49.0 billion by 2030, the market’s remarkable Compound Annual Growth Rate (CAGR) of 22.10% (2022-2030) underscores its strategic growth trajectory.

Key Highlights of the Report

The global novel drug delivery systems market is segmented by route of administration, mode of NDDS, and region. The oral drug delivery system is the most popular segment. Controlled drug delivery systems are the most commonly used mode of NDDS, with North America leading the market growth.

The global novel drug delivery systems market has several drivers, including the rising prevalence of chronic diseases like cancer, diabetes mellitus, coronary obstructive pulmonary diseases, ischemic heart diseases, and mental disorders. In addition, various technological developments in the medical field have expanded the range of specific tissue treatments and created the need for novel drug delivery systems to deliver more controlled drugs. However, the market also faces significant challenges, such as the growing use of generic medications.

Nonetheless, the global novel drug delivery systems market offers significant growth opportunities, including strategic cooperation, and introducing new products will accelerate market expansion.

What Are The Main Drivers Of The Global Novel drug delivery systems Market?

The global novel drug delivery systems market is driven by several factors, including globally increased COVID-19 vaccination rates, new product introductions, an increase in the frequency of chronic diseases, and the emergence of newer technologies.

What Are The Major Challenges Faced By The Global Novel drug delivery systems Market?

The global novel drug delivery systems market also faces several challenges, including the growing use of generic medications.

What Are The Growth Opportunities In The Global Novel drug delivery systems Market?

The global novel drug delivery systems market offers significant growth opportunities, including strategic cooperation, and introducing new products will accelerate market expansion.

Executive Summary

Overview of the Global Novel drug delivery systems Market

The global novel drug delivery systems market has been steadily growing in recent years, driven by globally increased COVID-19 vaccination rates, new product introductions, an increase in the frequency of chronic diseases, and the emergence of newer technologies. The market is characterized by a wide range of routes of administrations, and modes of NDDS, catering to diverse consumer preferences.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Definition

To increase the effectiveness and safety of medication, novel delivery systems (NDDS) are being developed. These systems aid in providing the proper medication dosage for the right amount of time at the correct location within the body. This can involve delivering medicine directly to a certain group of cells or organs, as is the case with cancer treatments, or maintaining a drug at a constant, effective level in the body while minimizing side effects and toxicity. Sustained drug action is a term used to describe how NDDS can affect how a drug behaves over time. To what extent a medicine is absorbed by the body and dispersed to various organs or tissues can be referred to in this sentence.

Market Insights

  • The global demand for novel drug delivery systems was valued at USD 12.1 Billion in 2022 and is expected to reach USD 49.0 Billion in 2030, growing at a CAGR of 22.10% between 2023 and 2030.
  • Oral drug delivery systems are the leading segment by route of administration and held over 43% share in terms of value in 2022,
  • The controlled drug delivery systems segment governs the demand for novel drug delivery systems globally, holding a massive share of over 80% in 2022, and is expected to grow at a rapid CAGR.
  • North America is fueling the growth of the novel drug delivery systems industry with over one-third share in 2022, while Asia Pacific and Europe collectively account for just under 50% share in 2022. Europe held over 22% share in 2022.
  • The main elements anticipated to propel NDDS market expansion in this area are rising healthcare costs, encouraging government initiatives, and the presence of important drug delivery system suppliers. At the same time, the growing use of generic medications is the main restraint.
  • Strategic cooperation and the introduction of new products will accelerate market expansion.

Segmentation by Route of Administration

  • Oral drug delivery systems are the leading segment by route of administration and held over 43% share in value in 2022.

Segmentation by Mode of NDDS

  • The controlled drug delivery systems segment governs the demand for novel drug delivery systems worldwide, holding a massive share of over 80% in 2022, and is also expected to grow at a rapid CAGR.

Segmentation by Region

  • North America is fueling the growth of the novel drug delivery systems industry with over one-third share in 2022.
  • Asia Pacific and Europe collectively account for just under 50% share in 2022, with Europe holding over 22% share in the same year.
  • The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for novel drug delivery systems.

The increasing demand for novel drug delivery systems can be attributed to the increased COVID-19 vaccination rates, new product introductions, an increase in the frequency of chronic diseases, and the emergence of newer technologies. However, the market is restrained by the growing use of generic medications.

The United States is one of the largest markets for novel drug delivery systems in North America, with a significant market share, due to variables like an increase in research projects looking into novel medicines, an increase in funding for developing novel drugs, and rising public awareness of novel drug delivery systems. In this area, chronic illnesses and ailments are becoming more prevalent. For instance, the GLOBOCAN predicted that in the United States in 2020, there will be 612,390 cancer-related deaths and 2,281,658 newly diagnosed cancer cases. Breast, lung, prostate, colorectal, bladder, and skin cancer are the most prevalent malignancies in the US. Additionally, several businesses are concentrating on developing novel drug delivery methods, market expansion, and new product launches, all of which are anticipated to drive market growth in the foreseeable future.

China is also a major market for novel drug delivery systems in the Asia Pacific region, with a significant market share. In the upcoming years, there are projected to be a lot of extremely profitable prospects in the market for new drug delivery systems in the Asia Pacific area. The growing interest in healthcare, rising R&D expenditures, rising need for minimally invasive procedures, and expanding accessibility to contemporary drug delivery systems are projected to be the major factors driving the potential for the market for novel drug delivery systems in this area.

Overall, the increasing demand for novel drug delivery systems can be attributed to the increased COVID-19 vaccination rates, new product introductions, an increase in the frequency of chronic diseases, and the emergence of newer technologies.

While the novel drug delivery systems market is growing, it faces challenges from the growing use of generic medications. Manufacturers are innovating and forming partnerships to stay competitive.

Use of Drug Delivery Technology in the Treatment of Chronic Diseases is Growing

Drug distribution has long been an essential component of treating many diseases, and thanks to advances in the field, its significance in treating most medical problems has increased. Over the past few years, there has been an exponential rise in the prevalence of chronic diseases like cancer, which has increased the demand for new systems for administering medications for medical treatments. Increased research and development efforts are anticipated to further progress the use of drug delivery in treating various chronic illnesses. Drug delivery technology has provided ground-breaking therapeutic techniques for treating chronic diseases like cancer.

Novel Drug Delivery Systems (NDDS) Market

Strict regulatory laws may stunt the potential market for NDDS.

Drug delivery systems must undergo a significant regulatory approval process before being introduced to the market and put to use. A difficulty and a hindrance to the market potential for innovative medication delivery systems is the existence of rigid criteria in the regulatory process. Over the next five years, this factor’s restraint on the industry is anticipated to remain in place.

Demand In North America

North America is currently at the forefront of the sector as a result of factors including an increase in the number of research programmes looking into innovative medications, an increase in financing for novel drug development, and increased public awareness of novel drug delivery methods. Ailments and chronic disorders are growing more common in this region. For instance, the GLOBOCAN forecasted 2,281,658 new cancer cases and 612,390 cancer-related deaths in the United States in 2020. The most common cancers in the US include skin, breast, lung, prostate, colorectal, and bladder cancers.

Additionally, several businesses are concentrating on developing novel drug delivery systems, market expansion, and introducing new products, all of which are anticipated to drive the market’s expansion throughout the projected period. For instance, Teva Pharmaceuticals USA introduced the AJOVY (fremanezumab-vfrm) autoinjector device in the United States in April 2020. This medication is approved for the prevention of migraine in adults. It is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine medication available in subcutaneous doses of 675 mg every three months or 225 mg every month. Similarly, Teva Pharmaceutical Industries Ltd. introduced Copaxone in March 2020 to treat patients with relapsing forms of multiple sclerosis (MS) in 50 countries, including Mexico, via the prefilled autoinjector YpsoMate from Ypsomed.

Thus, it is anticipated that such product introductions will accelerate market expansion. Thus, it is anticipated that during the forecast period, the market for new drug delivery systems in North America will be driven by the growing patient population with chronic diseases and the development and introduction of technologically sophisticated drug delivery systems.

Competitive Landscape

Key Players

The global novel drug delivery systems market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

  • Abbott Laboratories
  • Amgen Inc
  • AstraZeneca PLC
  • Bayer AG
  • Boston Scientific Corporation
  • Bristol-Myers Squibb
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.,
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc

These companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions to stay ahead in the market.

The major players in the global novel drug delivery systems market constantly strive to stay ahead by introducing new products and innovations.

In Germany, INBRIJA 33 mg (levodopa inhalation powder, hard capsules) was introduced in June 2022 by Esteve Pharmaceuticals GmbH. The intermittent management of episodic motor fluctuations in adult Parkinson’s disease patients receiving levodopa/dopa-decarboxylase inhibitor therapy indicates INBRIJA in the EU.

Thermo Fisher Scientific Company introduced a new IVD system for assay developers and clinical laboratories in November 2021 to support the growth of molecular diagnostics.

A cooperation was formed between EVERSANA and Accord BioPharma in June 2022 to support the recently released CAMCEVI (leuprolide) 42mg injection emulsion for treating advanced prostate cancer in adults.

Summary of Key Findings

  • Globally increased COVID-19 vaccination rates, new product introductions, an increase in the frequency of chronic diseases, and the emergence of newer technologies are driving market growth.
  • Market segmented by route of administration, mode of NDDS, and region.
  • Oral drug delivery systems are the most popular segment.
  • Controlled drug delivery systems are most commonly used for the mode of NDDS.
  • North America is leading market growth; the market is highly competitive with key players including Abbott Laboratories, Amgen Inc, AstraZeneca PLC, Bayer AG, Boston Scientific Corporation, Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals, Inc.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Future Outlook

  • Positive outlook for the global novel drug delivery systems market with significant growth potential in the North American region
  • Strategic cooperation and the introduction of new products will accelerate market expansion.
  • Challenges from the growing use of generic medications.
  • Key players to focus on product innovation, expanding market reach and maintaining competitive pricing to stay ahead in the market.

Segmentation

  • By Route of administration
    • Oral Drug Delivery Systems
    • Injectable Drug Delivery Systems
    • Pulmonary Drug Delivery Systems
    • Transdermal Drug Delivery Systems
    • Others
  • By Mode of NDDS
    • Targeted Drug Delivery Systems
    • Controlled Drug Delivery Systems
    • Modulated Drug Delivery Systems
  • By Region
  • North America
    • The US.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Novel Drug Delivery Systems Market
2.2. Global Novel Drug Delivery Systems Market, By Route of Administration
2.3. Global Novel Drug Delivery Systems Market, By Mode of NDDS
2.4. Global Novel Drug Delivery Systems Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Novel Drug Delivery Systems Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Route of Administration
3.5.2. Mode of NDDS
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Route of Administrations
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Route of Administration Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Novel Drug Delivery Systems Market, By Route of Administration
7.1. Global Novel Drug Delivery Systems Market Overview, by Route of Administration
7.1.1. Global Novel Drug Delivery Systems Market Revenue Share, By Route of Administration, 2022 Vs 2030 (in %)
7.2. Oral Drug Delivery Systems
7.2.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)
7.3. Injectable Drug Delivery Systems
7.3.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)
7.4. Pulmonary Drug Delivery Systems
7.4.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)
7.5. Transdermal Drug Delivery Systems
7.5.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)
7.6. Others
7.6.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)

8. Global Novel Drug Delivery Systems Market, By Mode of NDDS
8.1. Global Novel Drug Delivery Systems Market Overview, by Mode of NDDS
8.1.1. Global Novel Drug Delivery Systems Market, By Mode of NDDS, 2022 vs 2030 (in %)
8.2. Targeted Drug Delivery Systems
8.2.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)
8.3. Controlled Drug Delivery Systems
8.3.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)
8.4. Modulated Drug Delivery Systems
8.4.1. Global Novel Drug Delivery Systems Market, By Region, 2017-2030 (US$ Bn)

9. Global Novel Drug Delivery Systems Market, By Region
9.1. Global Novel Drug Delivery Systems Market Overview, by Region
9.1.1. Global Novel Drug Delivery Systems Market, By Region, 2022 vs 2030 (in%)
9.2. Route of Administration
9.2.1. Global Novel Drug Delivery Systems Market, By Route of Administration, 2017-2030 (US$ Bn)
9.3. Mode of NDDS
9.3.1. Global Novel Drug Delivery Systems Market, By Mode of NDDS, 2017-2030 (US$ Bn)

10. North America Novel Drug Delivery Systems Market Analysis
10.1. North America Novel Drug Delivery Systems Market, by Route of Administration, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Novel Drug Delivery Systems Market, by Country, 2017-2030 (US$ Bn)
10.3.1. North America Novel Drug Delivery Systems Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. U.S. Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
10.3.2.3. U.S. Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
10.3.3. Canada
10.3.3.1. Canada Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. Canada Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
10.3.3.3. Canada Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
10.3.4. Mexico
10.3.4.1. Mexico Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. Mexico Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
10.3.4.3. Mexico Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)

11. Europe Novel Drug Delivery Systems Market Analysis
11.1. Europe Novel Drug Delivery Systems Market, by Route of Administration, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Novel Drug Delivery Systems Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Europe Novel Drug Delivery Systems Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Germany Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
11.3.2.3. Germany Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
11.3.3. France
11.3.3.1. France Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. France Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
11.3.3.3. France Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
11.3.4. UK
11.3.4.1. UK Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.4.2. UK Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
11.3.4.3. UK Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
11.3.5. Italy
11.3.5.1. Italy Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.5.2. Italy Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
11.3.5.3. Italy Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
11.3.6. Spain
11.3.6.1. Spain Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.6.2. Spain Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
11.3.6.3. Spain Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.7.2. Rest of Europe Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
11.3.7.3. Rest of Europe Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)

12. Asia Pacific Novel Drug Delivery Systems Market Analysis
12.1. Asia Pacific Novel Drug Delivery Systems Market, by Route of Administration, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Novel Drug Delivery Systems Market, by Country, 2017-2030 (US$ Bn)
12.3.1. Asia Pacific Novel Drug Delivery Systems Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. China Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
12.3.2.3. China Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
12.3.3. Japan
12.3.3.1. Japan Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Japan Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
12.3.3.3. Japan Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
12.3.4. India
12.3.4.1. India Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.4.2. India Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
12.3.4.3. India Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
12.3.5. South Korea
12.3.5.1. South Korea Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.5.2. South Korea Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
12.3.5.3. South Korea Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.6.2. South-East Asia Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
12.3.6.3. South-East Asia Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.7.2. Rest of Asia Pacific Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
12.3.7.3. Rest of Asia Pacific Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)

13. Latin America Novel Drug Delivery Systems Market Analysis
13.1. Latin America Novel Drug Delivery Systems Market, by Route of Administration, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Novel Drug Delivery Systems Market, by Country, 2017-2030 (US$ Bn)
13.3.1. Latin America Novel Drug Delivery Systems Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.2.2. Brazil Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
13.3.2.3. Brazil Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
13.3.3. Argentina
13.3.3.1. Argentina Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.3.2. Argentina Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
13.3.3.3. Argentina Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.4.2. Rest of Latin America Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
13.3.4.3. Rest of Latin America Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)

14. Middle East and Africa Novel Drug Delivery Systems Market Analysis
14.1. Middle East and Africa Novel Drug Delivery Systems Market, by Route of Administration, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Novel Drug Delivery Systems Market, by Country, 2017-2030 (US$ Bn)
14.3.1. Middle East and Africa Novel Drug Delivery Systems Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.2.2. GCC Countries Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
14.3.2.3. GCC Countries Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
14.3.3. South Africa
14.3.3.1. South Africa Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.3.2. South Africa Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
14.3.3.3. South Africa Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Novel Drug Delivery Systems Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.4.2. Rest of Middle East and Africa Novel Drug Delivery Systems, By Route of Administration, 2017-2030 (US$ Bn)
14.3.4.3. Rest of Middle East and Africa Novel Drug Delivery Systems, By Mode of NDDS, 2017-2030 (US$ Bn)

15. Company Profiles
15.1. Abbott Laboratories
15.1.1. Company Overview
15.1.2. Products/Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. Amgen Inc
15.3. AstraZeneca PLC
15.4. Bayer AG
15.5. Boston Scientific Corporation
15.6. Bristol-Myers Squibb
15.7. Celgene Corporation
15.8. F. Hoffmann-La Roche AG
15.9. GlaxoSmithKline PLC
15.10. Johnson & Johnson
15.11. Merck & Co., Inc.,
15.12. Novartis AG
15.13. Pfizer Inc.
15.14. Spectrum Pharmaceuticals, Inc

List of Figures
FIG. 1 Global Novel Drug Delivery Systems Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Novel Drug Delivery Systems Market Segmentation
FIG. 4 Global Novel Drug Delivery Systems Market, by Route of Administration, 2022 (US$ Bn)
FIG. 5 Global Novel Drug Delivery Systems Market, by Mode of NDDS, 2022 (US$ Bn)
FIG. 6 Global Novel Drug Delivery Systems Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Route of Administration, 2022
FIG. 8 Attractive Investment Proposition, by Mode of NDDS, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Novel Drug Delivery Systems Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Novel Drug Delivery Systems Market Manufacturers, 2022
FIG. 12 Global Novel Drug Delivery Systems Market Value Contribution, By Route of Administration, 2022 & 2030 (Value %)
FIG. 13 Global Novel Drug Delivery Systems Market, by Oral Drug Delivery Systems, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Novel Drug Delivery Systems Market, by Injectable Drug Delivery Systems, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Novel Drug Delivery Systems Market, by Pulmonary Drug Delivery Systems, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Novel Drug Delivery Systems Market, by Transdermal Drug Delivery Systems, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Novel Drug Delivery Systems Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Novel Drug Delivery Systems Market Value Contribution, By Mode of NDDS, 2022 & 2030 (Value %)
FIG. 19 Global Novel Drug Delivery Systems Market, by Targeted Drug Delivery Systems, Value, 2017-2030 (US$ Bn)
FIG. 20 Global Novel Drug Delivery Systems Market, by Controlled Drug Delivery Systems, 2017-2030 (US$ Bn)
FIG. 21 Global Novel Drug Delivery Systems Market, by Modulated Drug Delivery Systems, 2017-2030 (US$ Bn)
FIG. 22 North America Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 23 U.S. Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 24 Canada Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 25 Europe Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 26 Germany Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 27 France Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 28 U.K. Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 29 Italy Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 30 Spain Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 31 Rest of Europe Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 32 Asia Pacific Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 33 China Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 34 Japan Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 35 India Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 36 South Korea Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 37 South-East Asia Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 38 Rest of Asia Pacific Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 39 Latin America Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 40 Brazil Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 41 Mexico Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 42 Rest of Latin America Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 43 Middle East & Africa Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 44 GCC Countries Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 45 South Africa Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)
FIG. 46 Rest of Middle East and Africa Novel Drug Delivery Systems Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Novel Drug Delivery Systems Market
TABLE 2 Global Novel Drug Delivery Systems Market: Market Drivers Impact Analysis
TABLE 3 Global Novel Drug Delivery Systems Market: Market Restraints Impact Analysis
TABLE 4 Global Novel Drug Delivery Systems Market, by Competitive Benchmarking, 2022
TABLE 5 Global Novel Drug Delivery Systems Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Novel Drug Delivery Systems Market, by Key Strategies Analysis, 2022
TABLE 7 Global Novel Drug Delivery Systems Market, by Oral Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Novel Drug Delivery Systems Market, by Oral Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Novel Drug Delivery Systems Market, by Injectable Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Novel Drug Delivery Systems Market, by Injectable Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Novel Drug Delivery Systems Market, by Pulmonary Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Novel Drug Delivery Systems Market, by Pulmonary Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Novel Drug Delivery Systems Market, by Transdermal Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Novel Drug Delivery Systems Market, by Transdermal Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Novel Drug Delivery Systems Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Novel Drug Delivery Systems Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Novel Drug Delivery Systems Market, by Control to Target (CTT) System, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Novel Drug Delivery Systems Market, by Control to Target (CTT) System, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Novel Drug Delivery Systems Market, by Targeted Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Novel Drug Delivery Systems Market, by Targeted Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Novel Drug Delivery Systems Market, by Controlled Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Novel Drug Delivery Systems Market, by Controlled Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Novel Drug Delivery Systems Market, by Modulated Drug Delivery Systems, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Novel Drug Delivery Systems Market, by Modulated Drug Delivery Systems, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 26 Global Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 27 Global Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 28 Global Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 29 Global Novel Drug Delivery Systems Market, by Region, 2017-2022 (US$ Bn)
TABLE 30 Global Novel Drug Delivery Systems Market, by Region, 2023-2030 (US$ Bn)
TABLE 31 North America Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 32 North America Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 33 North America Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 34 North America Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 35 North America Novel Drug Delivery Systems Market, by Country, 2017-2022 (US$ Bn)
TABLE 36 North America Novel Drug Delivery Systems Market, by Country, 2023-2030 (US$ Bn)
TABLE 37 United States Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 38 United States Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 39 United States Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 40 United States Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 41 Canada Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 42 Canada Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 43 Canada Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 44 Canada Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 45 Mexico Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 46 Mexico Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 47 Mexico Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 48 Mexico Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 49 Europe Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 50 Europe Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 51 Europe Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 52 Europe Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 53 Europe Novel Drug Delivery Systems Market, by Country, 2017-2022 (US$ Bn)
TABLE 54 Europe Novel Drug Delivery Systems Market, by Country, 2023-2030 (US$ Bn)
TABLE 55 Germany Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 56 Germany Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 57 Germany Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 58 Germany Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 59 France Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 60 France Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 61 France Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 62 France Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 63 United Kingdom Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 64 United Kingdom Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 65 United Kingdom Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 66 United Kingdom Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 67 Italy Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 68 Italy Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 69 Italy Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 70 Italy Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 71 Spain Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 72 Spain Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 73 Spain Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 74 Spain Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 75 Rest of Europe Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 76 Rest of Europe Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 77 Rest of Europe Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 78 Rest of Europe Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 79 Asia Pacific Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 80 Asia Pacific Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 81 Asia Pacific Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 82 Asia Pacific Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 83 China Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 84 China Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 85 China Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 86 China Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 87 Japan Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 88 Japan Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 89 Japan Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 90 Japan Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 91 India Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 92 India Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 93 India Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 94 India Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 95 South Korea Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 96 South Korea Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 97 South Korea Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 98 South Korea Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 99 South-East Asia Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 100 South-East Asia Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 101 South-East Asia Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 102 South-East Asia Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 103 Rest of Asia Pacific Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 104 Rest of Asia Pacific Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 105 Rest of Asia Pacific Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 106 Rest of Asia Pacific Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 107 Latin America Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 108 Latin America Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 109 Latin America Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 110 Latin America Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 111 Brazil Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 112 Brazil Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 113 Brazil Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 114 Brazil Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 115 Argentina Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 116 Argentina Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 117 Argentina Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 118 Argentina Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 119 Rest of Latin America Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 120 Rest of Latin America Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 121 Rest of Latin America Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 122 Rest of Latin America Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 123 Middle East and Africa Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 124 Middle East and Africa Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 125 Middle East and Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 126 Middle East and Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 127 GCC Countries Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 128 GCC Countries Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 129 GCC Countries Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 130 GCC Countries Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 131 South Africa Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 132 South Africa Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 133 South Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 134 South Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)
TABLE 135 Rest of Middle East and Africa Novel Drug Delivery Systems Market, by Route of Administration, 2017-2022 (US$ Bn)
TABLE 136 Rest of Middle East and Africa Novel Drug Delivery Systems Market, by Route of Administration, 2023-2030 (US$ Bn)
TABLE 137 Rest of Middle East and Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2017-2022 (US$ Bn)
TABLE 138 Rest of Middle East and Africa Novel Drug Delivery Systems Market, by Mode of NDDS, 2023-2030 (US$ Bn)

Frequently Asked Questions:

What is the current size of the global novel drug delivery systems market?

The global novel drug delivery systems market was valued at USD 12.1 Billion in 2022.

What is the expected growth rate of the novel drug delivery systems market between 2023 and 2030?

The novel drug delivery systems market is expected to grow at a CAGR of 22.10% between 2023 and 2030, reaching USD 49.0 Billion in 2030.

Which segment is leading the market share in terms of route of administration?

Oral drug delivery systems are the leading segment by route of administration, holding over 43% share in terms of value in 2022.

Which mode of NDDS segment governs the world’s demand for novel drug delivery systems?

The controlled drug delivery systems segment governs the demand for novel drug delivery systems in the world, holding a massive share of over 80% in 2022.

Which segment is expected to post the highest CAGR during the forecast period?

The targeted drug delivery systems segment is expected to post the highest CAGR during the forecast period.

Which region is fueling the growth of the novel drug delivery systems industry?

North America is fueling the growth of the novel drug delivery systems industry, with over one-third share in 2022.

Who are the major players in the global novel drug delivery systems market?

The top players include Abbott Laboratories, Amgen Inc, AstraZeneca PLC, Bayer AG, Boston Scientific Corporation, Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals, Inc.

What are the major market drivers of the novel drug delivery systems industry?

Globally increased COVID-19 vaccination rates, new product introductions, an increase in the frequency of chronic diseases, and the emergence of newer technologies are the major market drivers.

What are the major market restraints of the novel drug delivery systems industry?

The growing use of generic medications is the major market restraint.

What are the major market opportunities of the novel drug delivery systems industry?

Strategic cooperation and introducing new products are the major opportunities in the novel drug delivery systems industry.

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Anti-Cancer Drugs Market

Published:
Report ID: 39971

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Congenital Disabilities Market

Published:
Report ID: 39845

Acquired Hemophilia Treatment Market

Published:
Report ID: 1124

Tyrosine Kinase Inhibitors (TKIs) Market

Published:
Report ID: 39696

Peptide Therapeutics Market

Published:
Report ID: 9142

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN